{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:30:35Z","timestamp":1790789435091,"version":"4.1.0"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Unitaid"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Nigeria adopted dolutegravir (DTG) as part of first line (1L) antiretroviral therapy (ART) in 2017. However, there is limited documented experience using DTG in sub-Saharan Africa. Our study assessed DTG acceptability from the patient\u2019s perspective as well as treatment outcomes at 3 high-volume facilities in Nigeria. This is a mixed method prospective cohort study with 12 months of follow-up between July 2017 and January 2019. Patients who had intolerance or contraindications to non-nucleoside reverse-transcriptase inhibitors were included. Patient acceptability was assessed through one-on-one interviews at 2, 6, and 12 months following DTG initiation. ART-experienced participants were asked about side effects and regimen preference compared to their previous regimen. Viral load (VL) and CD4+ cell count tests were assessed according to the national schedule. Data were analysed in MS Excel and SAS 9.4. A total of 271 participants were enrolled on the study, the median age of participants was 45 years, 62% were female. 229 (206 ART-experienced, 23 ART-naive) of enrolled participants were interviewed at 12 months. 99.5% of ART-experienced study participants preferred DTG to their previous regimen. 32% of particpants reported at least one side effect. \u201cIncrease in appetite\u201d was most frequently reported (15%), followed by insomnia (10%) and bad dreams (10%). Average adherence as measured by drug pick-up was 99% and 3% reported a missed dose in the 3 days preceding their interview. Among participants with VL results (n = 199), 99% were virally suppressed (&lt;1000 copies\/ml), and 94% had VL &lt;50 copies\/ml at 12 months. This study is among the first to document self-reported patient experiences with DTG in sub-Saharan Africa and demonstrated high acceptability of DTG-based regimens among patients. The viral suppression rate was higher than the national average of 82%. Our findings support the recommendation of DTG-based regimen as the preferred 1L ART.<\/jats:p>","DOI":"10.1371\/journal.pone.0284767","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T17:38:17Z","timestamp":1684345097000},"page":"e0284767","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3823-303X","authenticated-orcid":true,"given":"Opeyemi","family":"Abudiore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikechukwu","family":"Amamilo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Williams","family":"Eigege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8853-9603","authenticated-orcid":true,"given":"Joseph","family":"Harwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Conroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justus","family":"Jiboye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folu","family":"Lufadeju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Amole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owens","family":"Wiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Anweh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oche Ochai","family":"Agbaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7424-6060","authenticated-orcid":true,"given":"Alani Sulaimon","family":"Akanmu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"pone.0284767.ref001","author":"National AIDS and STI Control Program, Federal Ministry of Health Nigeria.","year":"2016","journal-title":"2016 Annual Report on HIV\/AIDS Health Response in Nigeria"},{"key":"pone.0284767.ref002","author":"National AIDS and STI Control Program, Federal Ministry of Health Nigeria","year":"2016","journal-title":"National Guidelines for HIV Treatment Prevention and Care"},{"key":"pone.0284767.ref003","author":"Clinton Health Access Initiative","year":"2015","journal-title":"Case study: Improving HIV Treatment outcomes for patients on second line therapy through optimal regimen uptake."},{"issue":"9936","key":"pone.0284767.ref004","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48-week results from the randomised open-label phase 3b study.","volume":"383","author":"B Clotet","year":"2014","journal-title":"Lancet"},{"key":"pone.0284767.ref005","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus Abacavir\u2013Lamivudine for the Treatment of HIV-1 Infection","volume":"369","author":"S Walmsley","year":"2013","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0284767.ref006","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/QAD.0000000000000519","article-title":"Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trial","volume":"29","author":"F Raffi","year":"2015","journal-title":"AIDS"},{"issue":"11","key":"pone.0284767.ref007","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1097\/QAD.0b013e3283612419","article-title":"Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study","volume":"27","author":"H Stellbrink","year":"2013","journal-title":"AIDS"},{"issue":"9","key":"pone.0284767.ref008","doi-asserted-by":"crossref","first-page":"e105653","DOI":"10.1371\/journal.pone.0105653","article-title":"48-Week Efficacy and Safety of Dolutegravir Relative to Commonly Used Third Agents in Treatment-Naive HIV-1\u2013Infected Patients: A Systematic Review and Network Meta-Analysis.","volume":"9","author":"D Patel","year":"2014","journal-title":"PLoS ONE"},{"issue":"4","key":"pone.0284767.ref009","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/2040622314530461","article-title":"Dolutegravir: clinical efficacy and role in HIV therapy.","volume":"5","author":"A Fantauzzi","year":"2014","journal-title":"Ther Adv Chronic Dis."},{"key":"pone.0284767.ref010","author":"World Health Organization","year":"2018","journal-title":"Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV"},{"issue":"6","key":"pone.0284767.ref011","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/cid\/ciy763","article-title":"Tolerability, and Efficacy of Generic Dolutegravir-containing Antiretroviral Therapy Regimens Among South Indian Human Immunodeficiency Virus-infected Patients","volume":"68","author":"N Kumarasamy","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"1","key":"pone.0284767.ref012","doi-asserted-by":"crossref","first-page":"e25227","DOI":"10.1002\/jia2.25227","article-title":"Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort","volume":"22","author":"A Mondi","year":"2019","journal-title":"J Int AIDS Soc"},{"issue":"5","key":"pone.0284767.ref013","doi-asserted-by":"crossref","first-page":"e0232419","DOI":"10.1371\/journal.pone.0232419","article-title":"High acceptability and viral suppression of patients on Dolutegravir-based first-line regimens in pilot sites in Uganda: A mixed-methods prospective cohort study","volume":"15","author":"V. M. Nabitaka","year":"2020","journal-title":"PloS one"},{"issue":"2","key":"pone.0284767.ref014","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1473-3099(11)70290-0","article-title":"Once daily dolutegravir (S\/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48-week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.","volume":"12","author":"J Van-Lunzen","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"pone.0284767.ref015","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1056\/NEJM199507133330202","article-title":"Energy expenditure and wasting in human immunodeficiency virus infection","volume":"333","author":"D Macallan","year":"1995","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0284767.ref016","doi-asserted-by":"crossref","first-page":"322S","DOI":"10.1093\/jn\/133.1.322S","article-title":"Metabolic effects of infection on protein and energy status","volume":"133","author":"M Powanda","year":"2003","journal-title":"J Nutr"},{"issue":"2","key":"pone.0284767.ref017","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/ajcn\/53.2.437","article-title":"Resting energy expenditure is increased in stable, malnourished HIV-infected patients","volume":"53","author":"J Melchior","year":"1991","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"pone.0284767.ref018","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/ajcn\/55.2.455","article-title":"Resting energy expenditure, caloric intake, and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome","volume":"55","author":"C Grunfeld","year":"1992","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"pone.0284767.ref019","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/QAI.0000000000001525","article-title":"Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.","volume":"76","author":"J Norwood","year":"2017","journal-title":"J Acquir Immune Defic Syndr."},{"key":"pone.0284767.ref020","first-page":"21","article-title":"Progressive rises in weight and clinical obesity for TAF\/FTC\/DTG and TDF\/FTC\/DTG versus TDF\/FTC\/EFV: ADVANCE and NAMSAL trials","author":"A Hill","year":"2019","journal-title":"10th IAS conference of HIV Science"},{"issue":"7","key":"pone.0284767.ref021","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/cid\/ciz407","article-title":"Greater Weight Gain in Treatment Na\u00efve Persons Starting Dolutegravir-Based Antiretroviral Therapy","volume":"70","author":"K Bourgi","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pone.0284767.ref022","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/QAI.0000000000001269","article-title":"Psychiatric Symptoms in Patients Receiving Dolutegravir.","volume":"74","author":"A Fettiplace","year":"2017","journal-title":"J Acquir Immune Defic Syndr."},{"key":"pone.0284767.ref023","author":"World Health Organization","year":"2017","journal-title":"Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy"},{"issue":"1","key":"pone.0284767.ref024","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12879-021-05850-0","article-title":"Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-na\u00efve patients infected with HIV-1: an update on a systematic review and network meta-analysis.","volume":"21","author":"K Nickel","year":"2021","journal-title":"BMC Infect Dis."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0284767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T17:40:33Z","timestamp":1684345233000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0284767"}},"subtitle":[],"editor":[{"given":"Joel Msafiri","family":"Francis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":24,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0284767","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,17]]}}}